For a patient with prior illness‑triggered episodes that never fulfilled the full thrombotic microangiopathy (TMA) triad and now experiencing a complement activation‑related pseudo‑allergy (CARPA) reaction to an infusion, what limited laboratory or clinical findings can serve as supportive evidence for an underlying complement‑mediated TMA?

CARPA Reaction as Supportive Evidence for Complement-Mediated TMA

A CARPA reaction during infusion provides meaningful supportive evidence for underlying complement vulnerability in your patient, particularly when combined with recurrent illness-triggered episodes that show incomplete TMA features—this complement-mediated mechanism links both phenomena and should lower your threshold to pursue complement-directed workup and treatment.

Understanding the Mechanistic Connection

CARPA (complement activation-related pseudo-allergy) is fundamentally a complement-mediated reaction characterized by flushing, myalgias/arthralgias, back pain, and chest pressure without true anaphylaxis features 1. The key insight is that CARPA occurs through direct complement activation by nanoparticles or labile free iron, requiring no prior sensitization 1. This demonstrates that your patient's complement system is hyperreactive and prone to activation by external triggers.

The mechanistic overlap is critical: both CARPA and complement-mediated TMA share complement activation as their central pathophysiologic driver 2. If your patient's complement system activates robustly enough to produce clinical symptoms from an infusion, this same hyperreactive complement system could plausibly drive subclinical or incomplete TMA during illness-triggered episodes.

Diagnostic Approach for Incomplete TMA Presentations

Core Laboratory Findings to Document

Even without the complete triad, focus on these specific markers:

• Schistocytes on peripheral smear (even if <1-2%, document their presence) 3, 4
• LDH elevation with low haptoglobin (indicates hemolysis even without severe anemia) 4
• Platelet consumption pattern (≥25% decline from baseline, even if absolute count >150,000/mm³) 4
• Soluble C5b-9 (sC5b-9) elevation during acute episodes (direct evidence of terminal complement activation) 5, 6
• C3 and C4 levels during episodes (classical pathway: low C4; alternative pathway: low C3 with normal C4) 5
• Ba and Bb fragments (alternative pathway activation markers) 5

Critical Timing Considerations

Draw complement activation markers during or immediately after acute episodes, not during quiescent periods 6. Complement activation is dynamic and may normalize between events, leading to false-negative results if sampled too late.

Functional Complement Testing

Beyond standard complement levels, consider functional assays that directly demonstrate complement hyperactivity 7, 6:

• Modified Ham assay (demonstrates complement-mediated hemolysis)
• HMEC-1 C5b-9 deposition assay (shows complement deposition on endothelial cells under stress conditions)

These functional tests can reveal complement dysregulation even when genetic testing is negative or inconclusive 7, 6. However, do not delay treatment decisions waiting for functional assay results—they are adjunctive, not definitive 6.

Genetic Testing Strategy

Pursue complement gene panel testing including:

• CFH, CFI, CFB, C3, THBD, MCP, DGKE, PLG 8, 4

Important caveats:

• Negative genetic testing does NOT exclude complement-mediated TMA 8, 6
• 40-50% of complement-mediated TMA cases have no identifiable genetic variant 8, 6
• Variants of uncertain significance (VUS) are common and difficult to interpret 8

When to Treat Despite Incomplete Criteria

Lower your threshold for complement inhibition if:

1. Pattern recognition: Recurrent episodes triggered by illness with any TMA features (even incomplete) 6
2. CARPA reaction documented: Demonstrates complement hyperreactivity 1, 2
3. Progressive kidney injury: Rising creatinine during episodes that doesn't fully resolve 6
4. Elevated sC5b-9 during episodes: Direct evidence of complement activation 5, 6
5. Lack of improvement with supportive care alone: Suggests ongoing pathologic process 6

Practical Algorithm

During next acute episode:

1. Immediate labs: CBC with manual differential for schistocytes, LDH, haptoglobin, creatinine, urinalysis
2. Complement workup: C3, C4, sC5b-9, Ba/Bb fragments (if available)
3. Exclude TTP: ADAMTS13 activity (must be <10% to confirm TTP) 3
4. Exclude STEC-HUS: Stool culture for Shiga toxin if diarrhea present 4

If TMA features present with elevated complement markers:

• Start eculizumab empirically while awaiting confirmatory testing 9, 6
• Do not wait for genetic results 6
• Document response to treatment (platelet recovery, LDH normalization, creatinine stabilization)

Between episodes:

• Complete genetic testing
• Consider functional complement assays
• Document baseline complement levels for comparison

Common Pitfalls to Avoid

1. Waiting for the "complete triad" before acting—many complement-mediated TMA cases never show all three features simultaneously 4, 6
2. Dismissing mild thrombocytopenia (platelets 100-150K)—a 25% decline from baseline is significant 4
3. Sampling complement markers between episodes—activation may be transient 6
4. Over-relying on genetic testing—absence of variants doesn't exclude disease 8, 6
5. Attributing everything to the trigger—the trigger may unmask underlying complement dysregulation rather than being the sole cause 6, 10

Secondary vs. Primary Complement-Mediated TMA

Your patient's presentation (illness-triggered episodes) suggests secondary complement activation where infections unmask underlying complement vulnerability 10, 11. The CARPA reaction demonstrates this vulnerability exists at baseline. In this context, complement activation is real and pathogenic even if "secondary"—the distinction matters less for acute management than recognizing the need for complement inhibition 12, 11.

The key question is not whether a trigger exists, but whether the trigger fully explains the syndrome or whether complement dysregulation is driving irreversible organ injury 6. Your patient's recurrent pattern and CARPA history suggest the latter.